Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia

Leuk Res. 1993 Mar;17(3):291-3. doi: 10.1016/0145-2126(93)90014-c.

Abstract

The third exon of the c-myc gene contains a CpG site which has been implicated as a regulatory region. When this site is methylated it has protein binding properties and binds a different set of proteins in normal and neoplastic cells. Recent work using myeloma cell lines indicates a correlation between hypomethylation at this site and enhanced expression of the myc protein. We investigated the methylation of this site in 10 cases of myeloma but found that there was no change from the high degree of methylation found in normal cells. Therefore, methylation status at this site is unlikely to serve as a prognosticator in myelomatosis. However, methylation changes at this site were observed in DNA from two cases of CMML, in which hypomethylation was observed and in three AML cases, which were completely methylated at this site.

MeSH terms

  • Acute Disease
  • Biomarkers, Tumor / genetics*
  • Bone Marrow / physiology
  • DNA, Neoplasm / genetics
  • DNA, Neoplasm / metabolism
  • Deoxyribonuclease HpaII
  • Deoxyribonucleases, Type II Site-Specific / metabolism
  • Exons / physiology*
  • Genes, myc / genetics*
  • Humans
  • Leukemia, Myeloid / blood
  • Leukemia, Myeloid / genetics*
  • Leukemia, Myelomonocytic, Chronic / blood
  • Leukemia, Myelomonocytic, Chronic / genetics*
  • Methylation
  • Multiple Myeloma / blood
  • Multiple Myeloma / genetics*
  • Prognosis

Substances

  • Biomarkers, Tumor
  • DNA, Neoplasm
  • Deoxyribonuclease HpaII
  • Deoxyribonucleases, Type II Site-Specific